Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Apr. 02, 2023
Income Statement [Abstract]    
Revenue $ 5,272 $ 21
Cost of revenue 7,072 12,248
Gross margin (1,800) (12,227)
Operating expenses:    
Research and development 48,788 23,749
Selling, general and administrative 19,548 27,274
Total operating expenses 68,336 51,023
Loss from operations (70,136) (63,250)
Other income (expense):    
Change in fair value of common stock warrants 21,120 (12,840)
Interest income 3,560 2,466
Interest expense (1,659) 0
Other income, net 466 21
Total other income (expense), net 23,487 (10,353)
Loss before income tax benefit (46,649) (73,603)
Income tax benefit (152) 0
Net loss (46,497) (73,603)
Net loss attributable to non-controlling interests (129) 0
Net loss attributable to Enovix $ (46,368) $ (73,603)
Net loss per share attributable to Enovix shareholders, basic (in dollars per share) $ (0.28) $ (0.47)
Weighted average number of common shares outstanding, basic (in shares) 168,144,918 155,626,977
Net loss per share attributable to Enovix shareholders, diluted (in dollars per share) $ (0.28) $ (0.47)
Weighted average number of common shares outstanding, diluted (in shares) 168,144,918 155,626,977